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Taking patient reported outcomes centre
stage in cancer research – why has it taken
so long?
Peter Selby* and Galina Velikova
Plain English summary
Roger Wilson challenged cancer professionals in research and care to place the patient perspective and patient
reported outcome measures centre stage. The ability to collect information from patients using structured
questionnaires (known as Patient Reported Outcome Measures or PROMs) which ask about clinical issues (such as
disease symptoms or treatment side-effects) as well as social, emotional and psychological issues has existed for
40 years. They provide a powerful way of working out whether an aspect of diagnosis or treatment for cancer is
bringing real benefits to patients that can be measured using these structured questionnaires. When they are used,
studies and cancer service developments are clearly constrained to focus on what matters to patients rather than,
perhaps what matters to health service professionals or recent exciting but perhaps relatively unproven new
technologies. There is good evidence that PROMs can contribute valuable inputs into the results of randomised
controlled trials, clinical consultations and surveys of whole populations even at a national level. However, there is a
great deal more work to be done on methodology and perhaps to change attitudes and cultures within the
healthcare professions before they can deliver all of their potential to bring benefits to cancer patients.
Abstract
In response to Roger Wilson’s challenge to place a patient-centred approach using Patient Reported Outcome
Measures (PROMs) across all of the patient pathway, we have summarised progress over 40 years. We have critically
evaluated what has been achieved to use patient reported outcomes in randomised controlled trials, in routine
clinical practice and in population surveys. We conclude that there has been substantial scientific progress but that
it has, arguably, been relatively slow. Barriers to placing PROMs centre stage in all of these areas of activity remain
in methodology and to a degree in professional attitudes and culture. Active research programmes on
methodology and closer working between healthcare professionals, cancer patients and patient advocates are the
key requirements to speed up the use and application of PROMs and which should bring benefits to cancer
patients and healthcare services.
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We write in response to Roger Wilson’s thoughtful,
stimulating and challenging paper “Patient led PROMs
must take centre stage in cancer research”, published in
Research Involvement and Engagement. In the article he
takes an overview of cancer research, recognising the
progress that has been made both in cancer diagnosis
and treatment and in patient outcomes, but enters sub-
stantial and important challenges. Clinical researchers
and health service developers have yet to place the pa-
tient perspective and the patient-centred approach
centre stage. We have failed to exploit the opportunities
presented by Patient Reported Outcome Measures
(PROMs) that can help us do so. We essentially agree
with Roger Wilson. We have to do much better in pla-
cing patient perspective at the centre of cancer research
and of cancer care. We also agree that in doing so we
will take important steps towards tackling some of the
practical and cultural challenges which we have failed to
address adequately. The clinical and research commu-
nity remain much too ready to prioritise and emphasise
exciting new technologies whilst neglecting relatively
simple but firmly evidence based interventions which
have the potential to greatly improve patient outcomes
not only in terms of their survival but also in terms of
better patient experience and quality of life.
We are all rightly excited by the promise of new tech-
nologies in immunotherapy, genetics and personalised
medicine. However, as Roger Wilson points out, they re-
main a long way from delivering global improvements in
cancer outcomes. On the other hand simple measures
around public awareness, access to therapy, ensuring
that well established best practice is used widely across
healthcare systems and across different countries, and
the appropriate delivery of timely diagnosis and multi-
disciplinary specialised care have proven potential to im-
prove outcomes. It has been recently suggested [1] that
if we made proper use of well established existing good
practice, we could continue to improve the survival of
cancer patients from the approximately 50% long term
survival achieved in many European countries towards
the 60% long term survival that is achieved through best
practice in some European countries. It has also been es-
timated that if we make well planned and effective use
of research in new diagnostic and treatment approaches
derived from existing technologies, then it is realistic to
aim for a 70% long term survival or even better in as lit-
tle as two decades. However, if we are to achieve this we
have to understand the issues that Roger Wilson empha-
sises. We must ensure that we make the best use of what
is known whilst we also quickly take advantage of excit-
ing new cancer sciences.
The use of PROMs to evaluate progress will mean that
care and research are focused to address the issues that
really matter to patients. The wide uptake of Patient
Reported Outcomes and the impact that this has on the
culture of healthcare professionals will ensure that ser-
vices as a whole deliver what patients expect.
Unfortunately, the time lag between work on Patient
Reported Outcome Measures and their comprehensive
position in centre stage in cancer research is uncomfort-
ably long. PROMs in the form of health related quality
of life questionnaires were first proposed in 1976 by
Terry Priestman and Michael Baum in a seminal article
in the Lancet [2]. Their contribution was followed rea-
sonably quickly by programmes of work which took the
idea of health related quality of life and applied the con-
cepts of psychometrics to the development of the rele-
vant questionnaires, the evaluation of their psychometric
properties and their performance in the evaluation of in-
novations [2–5]. So by the early 90s we had well evalu-
ated formal tools that could be deployed in cancer
research and in cancer care with some confidence in
their performance. At that point workers in the field
faced many challenges. We can characterise three key
questions:
Can PROMs be used in randomised prospective
trials to collect data in a way that allows a
statement to be made about the impact on
patient’s quality of life including not only the
activity of the disease, but also emotional, social,
physical wellbeing?
Broadly the answer to the question about the value of
PROMs in clinical trials is strongly positive [6]. Building
particularly on the work of the EORTC (European Or-
ganisation for Research and Treatment of Cancer) with
their core Quality of Life questionnaire, QLQ-C30, and
David Cella and colleagues in North America with the
FACT questionnaires, it is possible to have comparative
data in a clinical trial that can give powerful relative
statements about how one group of patients compare to
another. It is still difficult to make comparisons between
different questionnaires in different studies but the rela-
tive performance of treatment strategies in answering
the specific questions that are posed within the trial has
been valuable. A powerful recent example is the Prostate
Testing for Cancer and Treatment (ProtecT) trial ad-
dressing very important and challenging questions
around the initial management of men with prostate
cancer. The rigorous and extensive use of PROMs in
that study allow us to see that even though there are im-
portant specific damaging effects of different treatments
which may have important consequences for sexual and
urological outcomes for men, overall the quality of life
achieved is eventually remarkably good for each of the
different treatment approaches [7]. Systematic reviews
have looked at the value of PROMs in aiding
decision-taking based upon randomised controlled trials.
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It is possible to include that the PROMs do aid
decision-making in a range of clinical trial settings [8].
Is it possible to use PROMs in routine clinical care
to improve consultations and clinical outcomes?
In some ways the challenge of using PROMs in routine
clinical care is methodologically even greater than their
use in randomised trials. In clinical care the information
has to be meaningful to both patient and clinician and
be accessible and useable in the consultation in real
time. Absolute interpretations are much more important
in this setting because there are no randomised con-
trolled groups for comparison.
This question has been studied carefully by a large
number of groups over the last two decades [9]. Jensen
et al. [9] and Kotronoulas et al. [10] have completed sys-
tematic reviews quite recently of the 25 randomised con-
trolled trials of this approach. They concluded that there
was still significant gaps in the evidence base but there
is indeed growing evidence in support of the use of rou-
tine PROM collection and the demonstration that it can
enable better patient-centred care in the setting of can-
cer. However, it is worth noting the results of a recent
randomised trial of systematic monitoring of patients’
symptoms using electronic PROMs which showed im-
proved clinician awareness of symptoms, better symp-
tom management, less emergency visits, better quality of
life and improved overall survival in patients receiving
chemotherapy for advanced cancer [11, 12].
Can we use PROMs in a meaningful way to survey
whole populations of cancer patients and the
general population?
It is now almost a decade since the Darzi Report recom-
mended that PROMs data should be an essential compo-
nent of healthcare evaluation in the United Kingdom
and the commitment was made in the NHS to use
PROMs in the development of world-class cancer out-
comes [13, 14]. There is progress. Large scale surveys of
prostate cancer survivors [15] and colorectal cancer pa-
tients [16] are generating valuable information on pa-
tient reported outcomes in national populations. They
demonstrate broadly that it is possible to achieve com-
parable quality of life of the cancer patient after cancer
treatment to the quality of life of the general population
although often with specific deficits that require atten-
tion. The commitment to move PROMs centre stage in
the UK NHS as part of the Cancer Dashboard is to be
welcomed but also approached cautiously because there
are still methodological challenges. Five pilot sites across
England are currently exploring ways to collect routinely
PROMs in the NHS to inform a national roll-out.
So we can point to quite hard evidence of reasonable
quality and quantity which shows us that PROMs can
contribute in randomised trials, routine practice and in
population surveys. So why has it taken 40 years to
reach this point and why, as Roger Wilson correctly
points out, are PROMs not centre stage in either cancer
research or cancer care? So some possible explanations
are worth consideration:
Psychometrics is a difficult science
There has to be a rigorous and relevant evaluation of a
performance of the questionnaires not only to ensure
that they are reliable and valid but also to be clear that
they tap into the appropriate domain of patient experi-
ence which they are seeking to measure. Patient input
here is essential and is a longstanding requirement of
the evaluation of psychometric properties of question-
naires. However, the process is time consuming, some-
times quite expensive and can involve large numbers of
patients or the general population to achieve meaningful
results. Individuals and groups have tended towards
“ownership” of their questionnaires. This may well re-
flect the efforts required to evaluate them adequately,
but has led to a lack of general consensus in the field
and a confusing number of questionnaires. This has slo-
wed down the generalisation and accessibility of these
methods in cancer research and care.
There are still pockets of professional resistance to the
engagement and empowerment of patients and to efforts
to tap into patient’s perceptions through the use of
PROMs
This remains the case despite the existence of evidence
that an engaged and empowered patient population can
promote better and more cost effective healthcare deliv-
ery [17].
There are external pressures on cancer professionals and
cancer patients which shift the focus away from the
patient perception and patient-centred care
Cancer sciences are truly exciting currently and funding
bodies, individuals and research institutions are all seek-
ing to demonstrate their success and prowess in such
exciting modern science. Indeed the psychosocial cancer
research community was horrified some years ago when
one of its most major and respected funders decided
that research in psychosocial oncology was no longer a
strategic priority for the organisation, and withdrew their
funding in this area in order to focus on research that
would lead towards cancer cure. This view fails to take
on board the importance of establishing a strong patient
perspective to ensure that those responsible for cancer
services remain grounded in the deliverable evidence
that is improving long term survival, as was discussed at
the beginning of this article.
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The Way Forward
So if we take on board Roger Wilson’s analysis and chal-
lenges what are the practical steps that may move
PROMs centre stage in cancer research with the attend-
ant benefits to cancer services, cancer patients and can-
cer outcomes?
 We do need to continue and sustain our efforts on
methodology. As Roger Wilson points out,
integrating quality of life measures across the whole
patient pathway and not, as most commonly in
randomised trials, to a single post-treatment time-
point. Quick and easy, reliable and valid question-
naires continue to elude us in many settings despite
the importance that is attached to quality adjust-
ment of survival by many healthcare systems. The
increased accessibility of electronic data collection
via Internet and mobile devices together with the
wide use of Electronic Patient Records featuring pa-
tient portals makes this approach possible and
feasible.
 The voice of cancer patients and patient advocates is
increasingly powerful with cancer professionals,
health service leaders and managers and government
health departments across the globe. It is being and
can be further raised to point out the value of
Patient Reported Outcome Measures in ensuring
that research and care and service development are
firmly grounded in the things that matter to patients
as a whole and things that are likely to work. We
need to redouble our efforts to simplify and clarify
and make more coherent messages for patients and
professionals that will keep them focused on
improving outcomes that matter to patients.
 Patient and public involvement as research partners
should be increasingly a core feature in PROM
development and application. Such involvement may
further contribute to the development of PROMs
that really do measure what matters, and are
relevant and acceptable to the end users.
 There are important training and education
challenges in all healthcare professionals and
oncology disciplines about patient-centred care and
the value of PROMs as a tool to support communi-
cation and shared decision-making to ensure effect-
ive patient-centred care [18].
 The dialogue about strategy, cancer research and
cancer care has to become a more evenly balanced
dialogue between patients, professionals, healthcare
commissioners and politicians.
Debates on cancer policy are inevitably going to be-
come more complex. However, a balanced approach that
involves professionals, patients and is informed by
Patient Reported Outcome Measures is much more
likely to generate progress in cancer research and cancer
care development that improves outcomes, patient ex-
perience and quality of life [1].
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